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Univariate Cox proportional hazard regression for 16 lncRNAs and risk scores for each cohort were calculated, respectively. Using the stepwise risk score threshold selection criterion, patients were classified into favorable and unfavorable risk score groups. Kaplan-Meier survival curves were used to estimate event free survival (EFS) and overall survival (OS). Multivariate Cox proportional hazard regression, ROC curve, and AUC analyses were performed to determine the prognostic independence and prediction accuracy for EFS.
Permutation test for 16 lncRNAs from the discovery cohort
To examine the chance of observed association, we randomized the survival time and relapse status of each patient 1000 times in the discovery cohort. We used this randomized survival data and the original expression values of lncRNAs and calculated the z-score for EFS estimated by univariate Cox regression. We repeated the above step 1000 times for each lncRNA. The average z-score obtained from this randomized survival data for each lncRNA was less than the observed z-score identified to be associated with advanced disease stage and aggressive phenotype (4-6). The neuroblastoma cohorts included in our study were unfortunately devoid of patient chromosomal segmental aberration information. Therefore, to evaluate expression of the 16-lncRNA signature in chromosomal segmental aberration, we first download the raw CEL files and clinical information of the microarray cohort with GEO accession number GSE13136 (7). The dataset consisted of 30 neuroblastoma patients were normalized and log2 transformed using the RMA normalization algorithm from the affy R package. Next, we extracted the expression profiles of 16 lncRNAs for MYCN status, chromosome 17 segmental (17q) gain status, and chromosome 1 segmental (1p) deletion status. We found that several of the 16-lncRNAs were differentially expressed (Supplementary Figures 16-18) .
Additionally, DNA ploidy of the tumor cell population also contributes to malignant neuroblastoma transformation (4-6). The hyperdiploid tumors characterize lower stage disease, children younger than 1 year of age, and it correlates with favorable prognosis. In contrast, diploid tumors characterize higher stage disease, and it correlates with unfavorable prognosis. In the independent cohort 2, consisted of 180 patients, of which 49 were diploid tumors and 90 were hyperdiploid tumors (Supplementary Table 7 ). The Kaplan-Meier analysis showed that patients with diploid tumors had a poor EFS (P = 0.00147) than patients with hyperdiploid tumors (Supplementary Figure 19A) . Next, we checked the 16-lncRNA signature risk scores in the DNA ploidy subgroups and found risk scores to be significantly higher in diploid subgroups (Supplementary Figure 19B) . The multivariate analysis was performed including MYCN status, age, DNA ploidy status and 16-lncRNA signature as a covariate. The analysis revealed age (HR = 23.24, P = 2.21E-03) and lncRNA signature (HR = 1.96, P = 7.88E-02) are independent prognostic factor associated with EFS (Supplementary Table 8 ). For lncRNA signature, the results are slightly over the 5% significance level. This may be because the independent cohort 2 was confounded by patient age and tumor stage (Supplementary Table 1) . Moreover, we also performed data stratification according to DNA ploidy status. Within each subgroup of the DNA ploidy status, patients were stratified into favorable and unfavorable risk score groups using the first quartile risk score threshold of the independent cohort 2 (Supplementary Figure 5) . We found lncRNA signature significantly stratified hyperdiploid tumors patients into two risk score groups (Supplementary Figure 20A) except the diploid tumor patients (Supplementary Figure   20B) .
SUPPLEMENTARY FIGURES
Supplementary Figure 1: Expression profiles of differentially expressed lncRNAs in the
Kaplan-Meier plots for the quartiles in each cohort. First, risk scores were arranged in increasing order and divided into quartiles. For the discovery cohort, the median risk score significantly separated patients into two risk score groups and the survival probability of event free survival is less than 50% in the unfavorable risk score groups. For the independent cohort 1, the first quartile risk score was chosen as the threshold value. For the independent cohort 2, the first quartile risk score was chosen as the threshold value. For the independent cohort 3, the median risk score was chosen as the threshold value. The P values were obtained using a Mantel log-rank test (two-sided). Colors represent risk groups.
Supplementary Figure 6: Survival estimates of overall survival in neuroblastoma patients.
Kaplan-Meier plots of favorable and unfavorable risk score groups based on the (A) median risk score of the discovery cohort (B) first quartile risk score of the independent cohort 1 (C) first quartile risk score of the independent cohort 2 (D) median risk score of the independent cohort 3.
The P values were obtained using a Mantel log-rank test (two-sided).
Supplementary Figure 7: Multivariate Cox analysis of the 16-lncRNA signature for overall survival in neuroblastoma patients.
Forest plot of the 16-lncRNA signature shows patients in the unfavorable risk score groups had poor overall survival rates and an independent predictor after adjusting for the clinical risk factors (except in the independent cohort 1). (A) Discovery cohort (B) Independent cohort 1 (C) Independent cohort 2 (D) Independent cohort 3. The hazard ratio (HR) and confidence interval (CI) are represented on a log 10 scale. All statistical tests were two-sided. HR = hazard ratio; CI = confidence interval.
(Figure continued)
Kaplan-Meier plots of the favorable and unfavorable risk score groups based on the first quartile risk score threshold value from the independent cohort 2. The patients were stratified according to (A-B) Age (C) High-risk (D) Stage 4 (E) MYCN non-amplified. The P values were obtained using a Mantel log-rank test (two-sided).
Supplementary Figure 11: Survival estimates of event free survival and overall survival within the clinical risk factors subgroups from the independent cohort 3.
Kaplan-Meier plots of the favorable and unfavorable risk score groups based on the median risk score threshold value from the independent cohort 3. The patients were stratified according to (A) Stage 4 (B) Stage 1, 2, 3, 4S (C) MYCN non-amplified. The P values were obtained using a Mantel log-rank test (two-sided). 
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(Figure continued on next page)
Enrichment plot shows highest enriched biological process for lncRNAs in common (A) Translational initiation for bad survival lncRNAs (B) Homophilic cell adhesion via plasma membrane adhesion molecules, adaptive immune response, and regulation of vesicle mediated transport for good survival lncRNAs. NES = normalized enrichment score; FDR = false discovery rate. 
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